Discontinued biological drugs in 2008.
This perspective is part of an ongoing series of articles that describe the drugs that were dropped from clinical development during the previous year. This paper focuses on those drugs that were discontinued in 2008. The drugs represent a diverse collection of compounds targeted at diseases including cancer, diabetes, infections, arthritis, HIV, restenosis, allergies, anaemia, osteoporosis, wound healing, and growth deficiency. No consistent theme is apparent that accounts for the diversity of discontinued drugs. Still, this diversity, coupled with the numbers of novel drugs that were approved in 2008 suggests a healthy ongoing drug development process.
Emerich
Dwaine F
DF
InCytu Inc, Lincoln, RI 02865, USA. ED3FJM@aol.com
D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use*; D055808:Drug Discovery; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D017211:Treatment Failure; D014612:Vaccines / Q000627:therapeutic use
D000890:Anti-Infective Agents; D000970:Antineoplastic Agents; D018501:Antirheumatic Agents; D001688:Biological Products; D007004:Hypoglycemic Agents; D014612:Vaccines